AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29672821
Drug: Atorvastatin 20
RxNorm normalized name: atorvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20 mg/day, up-titrated to 80 mg after 6 weeks
Trial: 29672821
Drug: Rosuvastatin 10
RxNorm normalized name: rosuvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 10 mg/day, up-titrated to 40 mg after 6 weeks
Trial: 27109860
Drug: 450 mg
RxNorm normalized name: aspirin 450 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 450 mg purified 5‐CGA
Trial: 27109860
Drug: 900 mg
RxNorm normalized name: diosmin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg purified 5‐CGA
Trial: 27109860
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg purified 5‐CGA (control group)
Trial: 27109860
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg purified (‐)‐epicatechin (positive control)
Trial: 23273022
Drug: Artemisinin-based combination
RxNorm normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemisinin-based combination therapy (ACT) for uncomplicated malaria
Trial: 20959430
Drug: L-arginine hydrochloride
DrugBank: L-arginine (DB17289)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine hydrochloride (30g infusion)
Trial: 16259308
Drug: Active laser
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active laser acupuncture (0.5J delivered to six to eight acupuncture sites, twice weekly for four weeks then weekly for a further four weeks)
Trial: 16259308
Drug: Sham control
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham control (inactive laser treatment)
Trial: 9762021
Drug: 0.005% calcipotriol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.005% calcipotriol ointment twice daily
Trial: 9762021
Drug: 0.3% tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3% tacrolimus ointment once daily
Trial: 9762021
Drug: Placebo ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ointment once daily
Trial: 3432357
Drug: L-tryptophan (L-TRP)
RxNorm normalized name: L-TRYPTOPHAN
DrugBank: Tryptophan (DB00150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-tryptophan (L-TRP) 2 g
Trial: 3432357
Drug: Very low
RxNorm normalized name: Very low fat spread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very low dose of L-tryptophan (0.04 g)
Trial: 31710104
Drug: Galcanezumab 120
RxNorm normalized name: Galcanezumab 120 mg/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galcanezumab 120 mg (with 240 mg loading dose)
Trial: 23439365
Drug: IDX184 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDX184 50 mg once daily + pegylated interferon-α2a and ribavirin
Trial: 23439365
Drug: IDX184 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDX184 50 mg twice daily + pegylated interferon-α2a and ribavirin
Trial: 23439365
Drug: IDX184 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDX184 100 mg once daily + pegylated interferon-α2a and ribavirin
Trial: 23439365
Drug: IDX184 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDX184 150 mg once daily + pegylated interferon-α2a and ribavirin
Trial: 23439365
Drug: IDX184 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDX184 100 mg twice daily + pegylated interferon-α2a and ribavirin
Trial: 23439365
Drug: IDX184 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDX184 200 mg once daily + pegylated interferon-α2a and ribavirin
Trial: 22080004
Drug: 0.4 mL
RxNorm normalized name: ethanol 0.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mL diluent-injected control
Trial: 22080004
Drug: All carbohydrate
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All carbohydrate treatments except glucose and dextrin combination
Trial: 22080004
Drug: All carbohydrates
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All carbohydrates except for 25% dextrin treatment
Trial: 17228991
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (decaffeinated coffee)
Trial: 17228991
Drug: Caffeine (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (both treatments)
Trial: 8403960
Drug: Methohexital (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methohexital (5 mg/mL)
Trial: 8403960
Drug: Midazolam (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.5 mg/mL)
Trial: 27045953
Drug: Engage in
RxNorm normalized name: Bispecific t-cell engager antibody regn4018
DrugBank: Ubamatamab (DB18875)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Engage in Education‐London (EiE‐L) intervention
Trial: 25193590
Drug: Honey, antibiotic,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Honey, antibiotic, and acetaminophen
Trial: 25193590
Drug: Antibiotic and
RxNorm normalized name: Triple Antibiotic And Pain Relief
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotic and acetaminophen
Trial: 22006408
Drug: Tegobuvir 40
RxNorm normalized name: Tegobuvir
DrugBank: Tegobuvir (DB11852)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegobuvir 40 mg BID + GS-9256 75 mg BID
Trial: 22006408
Drug: Tegobuvir 40
RxNorm normalized name: Tegobuvir
DrugBank: Tegobuvir (DB11852)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegobuvir 40 mg BID + GS-9256 75 mg BID + RBV 1,000-1,200 mg daily
Trial: 22006408
Drug: Tegobuvir 40
RxNorm normalized name: Tegobuvir
DrugBank: Tegobuvir (DB11852)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegobuvir 40 mg BID + GS-9256 75 mg BID + Peg-IFN alpha-2a (180 μg once-weekly) + RBV
Trial: 10673254
Drug: Dipyridamole 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyridamole 0.5 mg/kg infused intravenously for 3 minutes immediately before reperfusion during primary PTCA.
Trial: 10673254
Drug: Dipyridamole 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyridamole 0.5 mg/kg infused intravenously while continuous ECG recordings were obtained.
Trial: 6340825
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus immunotherapy with BCG-CWS
Trial: 26659931
Drug: Crisaborole topical
RxNorm normalized name: crisaborole topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crisaborole topical ointment 2% applied twice daily (BID)
Trial: 26659931
Drug: Crisaborole topical
RxNorm normalized name: crisaborole topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crisaborole topical ointment 0.5% or 2% applied once daily (QD)
Trial: 26659931
Drug: Crisaborole topical
RxNorm normalized name: crisaborole topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crisaborole topical ointment 0.5% or 2% applied twice daily (BID)
Trial: 22971742
Drug: midazolam +
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: midazolam + tramadol (1 mg/kg)
Trial: 21514637
Drug: Methotrexate (10-22.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (10-22.5 mg/wk)
Trial: 21514637
Drug: Azathioprine (1.5-2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azathioprine (1.5-2.5 mg/kg/d)
Trial: 18030515
Drug: NSAID therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAID therapy followed by methotrexate (MTX) for 3 months after 3 months of NSAID therapy
Trial: 18030515
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of NSAID and MTX for the entire 6-month period
Trial: 17205826
Drug: Compound decoctum
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound decoctum of Tripterygium wilfordii (TW) and liquorice
Trial: 17205826
Drug: Tripterygium wilfordii
RxNorm normalized name: TRIPTERYGIUM WILFORDII ROOT
DrugBank: Tripterygium wilfordii whole (DB14277)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tripterygium wilfordii ployglycosidium tablets
Trial: 14638353
Drug: Vitamins E
RxNorm normalized name: Multiple Vitamins Essentials
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamins E and C (1000 IU and 1000 mg, respectively) daily for 6 months
Trial: 11125871
Drug: Midazolam 12
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam 12 mg + Caffeine 250 mg
Trial: 11125871
Drug: Midazolam 12
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam 12 mg + Caffeine 125 mg
Trial: 6139119
Drug: Midazolam 12
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam 12 mg
Trial: 31092895
Drug: Once-weekly carfilzomib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly carfilzomib 70 mg/m2 (Kd70 mg/m2)
Trial: 31092895
Drug: Twice-weekly carfilzomib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly carfilzomib 27 mg/m2 (Kd27 mg/m2)
Trial: 28259322
Drug: Combination analgesics
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination analgesics
Trial: 15327411
Drug: Adefovir dipivoxil
RxNorm normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Adefovir dipivoxil (ADV) 10 mg daily
Trial: 17941284
Drug: Fexofenadine hydrochloride,
RxNorm normalized name: Fexofenadine Hydrochloride, 30 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fexofenadine hydrochloride, 30 mg, twice daily for 2 weeks
Trial: 17941284
Drug: Placebo, twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, twice daily for 2 weeks
Trial: 11562661
Drug: Gelatin-coated Dacron
RxNorm normalized name: simethicone
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gelatin-coated Dacron (GEL-D) grafts (n = 109)
Trial: 11562661
Drug: Gelatin-coated Dacron
RxNorm normalized name: simethicone
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gelatin-coated Dacron (GEL-D) grafts
Trial: 11562661
Drug: Dacron grafts
RxNorm normalized name: polyvinyl alcohol graft polyethylene glycol copolymer (3:1; 45000 MW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dacron grafts (GEL-D and COL-D combined)
Trial: 9622279
Drug: 0.5, 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5, 1 or 2 mg/day of oral micronized 17beta‐estradiol
Trial: 3216364
Drug: Cefamandole (1-g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefamandole (1-g intravenous dose)
Trial: 3216364
Drug: Cefotaxime (1-g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime (1-g intravenous dose)
Trial: 30479292
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care plus increased educational information regarding bowel preparation
Trial: 30479292
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care plus increased educational information regarding bowel preparation plus an anti-flatulent medication
Trial: 17163273
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg/day + Amoxicillin 1500 mg/day + Clarithromycin 400 mg/day
Trial: 17163273
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg/day + Amoxicillin 1500 mg/day + Clarithromycin 800 mg/day
Trial: 8314475
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose interferon (10 million units (MU) given six times a week for two weeks followed by 12 weeks of thrice weekly dosing
Trial: 8314475
Drug: Four weeks
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four weeks of 10 MU six times a week followed by eight weeks of thrice weekly dosing
Trial: 2963306
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of a third generation cephalosporin (cefotaxime or ceftazidime) and a new quinolone (pefloxacin)
Trial: 21340523
Drug: MISPTT (minimally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MISPTT (minimally invasive stereotactic puncture and thrombolysis therapy)
Trial: 21340523
Drug: Conventional craniotomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional craniotomy (CC)
Trial: 15337974
Drug: Short 30‐G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short 30‐G x 0.40 x 6 mm gauge needle
Trial: 15337974
Drug: Conventional 25‐G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional 25‐G x 0.50 x 13 mm gauge needle
Trial: 23657457
Drug: Breakfasts prepared
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breakfasts prepared with virgin olive oil (400 μg mL(‐1) of phenolic compounds)
Trial: 23657457
Drug: Breakfasts prepared
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breakfasts prepared with sunflower oils (pure, enriched with dimethylsiloxane, and enriched with phenolic compounds)
Trial: 20735877
Drug: Tomato purée
RxNorm normalized name: Tomato
DrugBank: Tomato (DB10573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tomato purée (70 g)
Trial: 19465371
Drug: Manual therapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy, exercise, and intermittent cervical traction (MTEXTraction group)
Trial: 19465371
Drug: Manual therapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy, exercise, and sham intermittent cervical traction (MTEX group)
Trial: 15223728
Drug: Losartan 50-100
RxNorm normalized name: losartan
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Losartan 50-100 mg o.d.
Trial: 15223728
Drug: Hydrochlorothiazide 12.5-25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 12.5-25 mg o.d.
Trial: 11966693
Drug: Short-contact dithranol
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-contact dithranol cream followed by clobetasol-17-propionate ointment 5 days per week
Trial: 11966693
Drug: Short-contact dithranol
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-contact dithranol cream followed by vehicle of clobetasol-17-propionate ointment
Trial: 11966693
Drug: Clobetasol-17-propionate ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clobetasol-17-propionate ointment 5 days per week
Trial: 7714225
Drug: Oral progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral progesterone 300 mg plus intravenous triazolam
Trial: 7714225
Drug: Intravenous triazolam
RxNorm normalized name: Triazolam
DrugBank: Triazolam (DB00897)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous triazolam plus oral placebo
Trial: 25532076
Drug: Cariprazine 3-12
RxNorm normalized name: cariprazine 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cariprazine 3-12 mg/day
Trial: 16790625
Drug: Dexmedetomidine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.5 microg/kg bolus over 10 min, followed by continuous infusion of 0.5 microg.kg(‐1).h(‐1))
Trial: 15609652
Drug: Short-duration prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-duration prophylaxis with 4 g of cefmetazole sodium for 2 days
Trial: 15609652
Drug: Long-duration prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-duration prophylaxis with 14 g of cefmetazole sodium for 7 days
Trial: 11603137
Drug: 30 mL
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mL 0.5% lignocaine and 50 mg tramadol (group B)
Trial: 11603137
Drug: 30 mL
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mL 0.5% lignocaine and 1 mL normal saline (group A)
Trial: 9600792
Drug: Withdrawal period
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal period after ibandronate treatment
Trial: 8083112
Drug: Sucralfate mouth
RxNorm normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucralfate mouth washing 1 g six times daily during irradiation (n = 20)
Trial: 2503553
Drug: Inhaled lysine-aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled lysine-aspirin
Trial: 2503553
Drug: Inhaled lysine-aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled lysine-aspirin with terfenadine premedication
Trial: 31958285
Drug: Upper limb
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Upper limb exercise programme (30-min daily for 12 weeks)
Trial: 29946179
Drug: Norfloxacin 400
RxNorm normalized name: norfloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin 400 mg daily
Trial: 29946179
Drug: Ciprofloxacin once
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin once weekly
Trial: 24461029
Drug: Curcumin formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin formulation with hydrophilic carrier, cellulosic derivatives and natural antioxidants (CHC)
Trial: 24461029
Drug: Curcumin phytosome
RxNorm normalized name: Jarrow Formulas Curcumin Phytosome Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin phytosome formulation (CP)
Trial: 24461029
Drug: Formulation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation with volatile oils of turmeric rhizome (CTR)
Trial: 22124354
Drug: Caffeine-containing energy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine-containing energy drink (179 mg)
Trial: 16352794
Drug: BNP levels
RxNorm normalized name: BNP
DrugBank: Nesiritide (DB04899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BNP levels >80 pg/mL at study entry
Trial: 16352794
Drug: BNP levels
RxNorm normalized name: BNP
DrugBank: Nesiritide (DB04899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BNP levels >80 pg/mL at 4 months
Trial: 16352794
Drug: BNP levels
RxNorm normalized name: BNP
DrugBank: Nesiritide (DB04899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BNP levels >80 pg/mL at 12 months
Trial: 16352794
Drug: BNP levels
RxNorm normalized name: BNP
DrugBank: Nesiritide (DB04899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BNP levels <80 pg/mL at study entry and <80 pg/mL at 4 months
Trial: 11926785
Drug: Split treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split treatment (human regular insulin at dinner and NPH insulin at bedtime)
Trial: 11926785
Drug: Mixed treatment
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed treatment (a mixture of human regular and NPH insulin administered before dinner)
Trial: 11926785
Drug: Split treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split treatment
Trial: 11926785
Drug: Mixed treatment
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed treatment
Trial: 10426343
Drug: Natural progesterone
RxNorm normalized name: NATURAL PROGESTERONE CREAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural progesterone (vaginal cream)
Trial: 540460
Drug: 160 mg
RxNorm normalized name: nadolol 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 mg of long-acting propranolol
Trial: 540460
Drug: 160 mg
RxNorm normalized name: nadolol 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 mg of standard propranolol
Trial: 540460
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of sotalol
Trial: 540460
Drug: 160 mg
RxNorm normalized name: nadolol 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 mg of oxprenolol
Trial: 540460
Drug: 160 mg
RxNorm normalized name: nadolol 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 mg of slow-release oxprenolol
Trial: 31805840
Drug: Narrative group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrative group therapy
Trial: 18615497
Drug: CBT‐G/antidepressant combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBT‐G/antidepressant combination
Trial: 18615497
Drug: Antidepressant alone
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant alone
Trial: 15241906
Drug: Prompt‐L‐Pop, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prompt‐L‐Pop, a 1‐step self‐etching primer ('all‐in‐one') (n = 52)
Trial: 1995917
Drug: Total fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total fat intake (77 g per day)
Trial: 17901162
Drug: Nurse led
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse led intermediate care package including initial pulmonary rehabilitation, self‐management education, written COPD action plan, monthly telephone calls, and 3 monthly home visits by a specialist nurse for 2 years
Trial: 16823355
Drug: Maltodextrins ingestion
RxNorm normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maltodextrins ingestion (0.7 g x kg(-1) body mass)
Trial: 10590187
Drug: Aspirin therapy
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin therapy (81 or 325 mg)